Acitretin belongs to a group of drugs known as retinoids. Retinoids include natural and synthetic compounds that have similar activity to vitamin A. Vitamin A helps regulate the immune system; impacts cellular growth, differentiation, proliferation; and plays a role in embryonic development. Other effects of retinoids include immunologic anti-inflammatory effects, induction of apoptosis, and inhibition of tumor promotion.
Vitamin A exists as retinol (vitamin A alcohol), retinal (vitamin A aldehyde), and retinoic acid (RA, vitamin A acid). The body cannot synthesize Vitamin A; therefore; it is acquired through diets such as eggs and milk. Carotenoids are precursors of vitamin A that are synthesized by plants. In the intestines, beta-carotene is converted to retinal then absorbed. Each molecule of beta-carotene is converted into two molecules of retinal. Animals with vitamin A deficiency have been observed to have epidermal hyperkeratosis, squamous metaplasia of mucous membranes and precancerous lesions.
Currently, three generations of synthetic retinoids exist. First generation retinoids include tretinoin (all-trans RA), isotretinoin (13-cis-retinoic acid), and alitretinoin (9-cis RA). Second generation retinoids include etretinate and acitretin. Third generation retinoids include adapalene, tazarotene, and bexarotene. In 1972, Bolag developed two aromatic retinoids: etretinate and acitretin. Acitretin is the retinoic acid metabolite of etretinate. Acitretin is relatively water soluble in comparison and has a little deposition in adipose tissue.
Acitretin is FDA-approved for psoriasis (severe plaque-type psoriasis, pustular psoriasis generalized, pustular psoriasis localized, combination therapy with ultraviolet B (UVB) or psoralen ultraviolet A (PUVA), combination therapy with cyclosporine, combination therapy with biologic therapies. Acitretin is the only systemic retinoid that is FDA-approved for psoriasis and effective as monotherapy.
Acitretin has been used off-label in dermatology for other uses. In those with solid organ transplant, acitretin has been used as a chemoprevention measure for nonmelanoma skin cancers. Acitretin has also been used for Darier disease, pityriasis rubra pilaris (PRP), and ichthyoses such as lamellar ichthyosis. Additionally, acitretin has been used in Grover disease (transient acantholytic dermatosis), lichen planus, and lupus erythematosus.
Retinoids bind cytosolic retinoic acid binding protein (CRABP) that acts as the intracellular carrier transporting it to the nucleus. In the nucleus, retinoids impact transcription by binding of two families of nuclear receptors: retinoic acid receptors (RAR) and retinoid X receptors (RXR). RAR and RXR families contain three receptor subtypes: alpha, beta, and gamma that are encoded by different genes. RAR can bind with RXR forming a heterodimer. RXR can bind with itself forming a homodimer or bind with other nuclear receptors such as thyroid hormone receptor, vitamin D3 receptor, and peripheral peroxidase activating receptor (PPAR). Dimers of RAR/RXR or RXR/RXR bind to DNA regulatory sequences in the promoter region, retinoid acid response elements (RAREs). Once the ligand binds, it undergoes a conformational change to release co-repressors and recruit co-activators. The retinoid-receptor complex may antagonize the action of other transcription factors thus working indirectly. Acitretin competes with RA for CRABP. Acitretin activates but does not bind to multiple RAR.
Acitretin has anti-inflammatory and anti-proliferative effects. It normalizes keratinocyte differentiation in the epithelium. It also hinders the expression of the proinflammatory cytokines like interleukin-6 (IL-6), migration inhibitory factor-related protein-8 (MRP-8), and interferon-gamma. The agent acts by binding and activating all nuclear subtypes of retinoid X-receptors and retinoic acid receptors.
The initial metabolism of acitretin involves isomerization. This differs from isotretinoin where initial metabolism is oxidation. Acitretin is converted to isoacitretin. Acitretin is ultimately eliminated in the bile as beta-glucuronide derivatives or through the kidneys as soluble metabolites.
Acitretin can undergo reverse metabolism to etretinate with acitretin is used in combination with alcohol.
Initial: Administer 25 to 50 mg orally daily as a single dose with the main meal.
Maintenance: Administer 25 to 50 mg orally daily after initial response to treatment. The maintenance dose should be based on clinical efficacy and tolerability.
In psoriasis treatment with acitretin, improvement is seen approximately at weeks 4 to 6. Maximum benefit may take between 3 to 4 months. Treatment dosing is initiated at 25 mg orally once daily. When the disease is stable, dosing is often reduced to 10 mg orally once daily or 25 mg orally every other day as a maintenance protocol. Treatment with acitretin leads to decreased plaque thickness, scaling, and pruritis. However, there is not much reduction in body surface area (BSA).
In combination with phototherapy, dosing is recommended at 25 mg orally once daily for 2 weeks prior to phototherapy with a need to decrease initial dose of ultraviolet (UV) light. If a patient is already on a stable dose of UV light and is starting acitretin, reduce the dose by 30% to 50% approximately 7 days after initiation of acitretin.
Capillary leak syndrome, exfoliative dermatitis, hypercholesterolemia, increased liver enzymes, increased creatinine phosphokinase, hepatotoxicity, hyperesthesia, paresthesia, rigors, cheilitis, alopecia, exfoliation of skin, xeroderma, nail disease, pruritus, erythematous rash, paronychia, hypertriglyceridemia, hyperglycemia, hypoglycemia, reticulocytosis, xerophthalmia, rhinitis, pseudotumor cerebri, tinnitus, and epistaxis.
United States Boxed Warning
Hypersensitivity to drug or components, pregnancy, intent to become pregnant within 3 years after treatment discontinuation, severe hepatic or renal dysfunction, chronic abnormally elevated blood lipid levels, or concomitant use with methotrexate or tetracyclines.
It is vital that clinicians who prescribe acitretin to women of childbearing age ensure that the female does not get pregnant for at least 3 years after discontinuing the medication.
United States Boxed Warning
Female patients should abstain from ethanol during therapy and for at least 2 months after discontinuing therapy.
Individuals who are prescribed acitretin are also advised against giving blood donations for at least 3 years. The drug is known to remain in the blood for a long time, and the risk of a birth defect is high.
Acitretin is frequently used to treat a number of skin disorders including acne, psoriasis, lichen planus, and discoid lupus. While the drug is effective, it is important for healthcare workers including pharmacists, nurse practitioners and the primary care physician to know its potential adverse effects. The drug should never be prescribed to a pregnant female because of the risk of teratogenicity. In addition, the FDA has issued several boxed warnings about the risk of hepatitis when the agent is combined with alcohol. When acitretin is prescribed, the patient must be educated on the potential adverse effects and the importance of avoiding alcohol.
|||Ighani A,Partridge ACR,Shear NH,Lynde C,Gulliver WP,Sibbald C,Fleming P, Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents. Journal of cutaneous medicine and surgery. 2018 Nov 21 [PubMed PMID: 30463416]|
|||Skillen LA,Corry A, Combination therapy of sirolimus and acitretin in solid organ transplant recipients: a new cutaneous adverse event. Clinical and experimental dermatology. 2018 Nov 14 [PubMed PMID: 30430627]|
|||Mehrtens SH,de la Hera I,Shankar S, Case of keratoacanthoma centrifugum marginatum treated with acitretin. BMJ case reports. 2018 Nov 1 [PubMed PMID: 30389737]|
|||Kaushik SB,Lebwohl MG, Review of safety and efficacy of approved systemic psoriasis therapies. International journal of dermatology. 2018 Sep 23 [PubMed PMID: 30246393]|
|||Chen W,Zhang X,Zhang W,Peng C,Zhu W,Chen X, Polymorphisms of SLCO1B1 rs4149056 and SLC22A1 rs2282143 are associated with responsiveness to acitretin in psoriasis patients. Scientific reports. 2018 Sep 4 [PubMed PMID: 30181619]|
|||Guenther LC,Kunynetz R,Lynde CW,Sibbald RG,Toole J,Vender R,Zip C, Acitretin Use in Dermatology. Journal of cutaneous medicine and surgery. 2017 Nov/Dec [PubMed PMID: 28952335]|
|||Chiricozzi A,Panduri S,Dini V,Tonini A,Gualtieri B,Romanelli M, Optimizing acitretin use in patients with plaque psoriasis. Dermatologic therapy. 2017 Mar [PubMed PMID: 27998019]|
|||Ortiz NE,Nijhawan RI,Weinberg JM, Acitretin. Dermatologic therapy. 2013 Sep-Oct [PubMed PMID: 24099069]|
|||Dunn LK,Gaar LR,Yentzer BA,O'Neill JL,Feldman SR, Acitretin in dermatology: a review. Journal of drugs in dermatology : JDD. 2011 Jul [PubMed PMID: 21720660]|